The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials.

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding The authors have no financial support to declare."

"Four electronic databases, including PubMed, Embase, Cochrane, and Web of Science, have been researched. This systematic study explored the efficacy and safety of anti-EGFR targeted agents in combination with chemotherapy in patients with potentially resectable mCRC. Articles published in English from inception until January 2023 were searched. The following search terms and keywords were used in the retrieval process: “anti-EGFR targeted agents,” “epidermal growth factor receptor targeted agents,” “panitumumab,” “cetuximab,” “colorectal liver metastasis,” and “metastatic colorectal cancer” (Supplementary Table ). In addition, data could also be derived from the reference lists of studies, and this meta-analysis complies with the Preferred Reporting Items Systematic reviews and Meta-Analyses (PRISMA) guidelines for the systematic review and meta-analysis []. The study protocol has registered with the PROSPERO: CRD42022340523 (https://www.crd.york.ac.uk/PROSPERO/). Methods: A systematic search was conducted on PubMed, Web of Science, Embase, and Cochrane Library. And all relevant studies published in English before January 2023 were collected to explore the impact of additional anti-EGFR targeted agent on the efficacy and safety of patients with potentially resectable mCRC (PROSPERO: CRD42022340523, https://www.crd.york.ac.uk/PROSPERO/)."